Tag: $Sarepta

BMO Capital and Piper Sandler downgraded Sarepta Therapeutics (NASDAQ:SRPT) after the company reported a second death linked to its gene therapy Elevidys in a non-ambulatory Duchenne muscular dystrophy (DMD) patient.

Sarepta Therapeutics Inc.’s (SRPT) gene therapy received expanded US approval to include more children with a deadly muscle disease, expanding the market for a controversial treatment that still hasn’t proved its benefit in clinical trials.